Although the addition of Voxelotor therapy to the drugs already available for SCD patients is highly desirable, physicians and scientists should be aware of its interference with laboratory tests that are routinely performed to measure HbS levels, and other Hb Variants. The gene discussed is GSTM1; the disease is Schnyder corneal dystrophy.